Vietnam Pharmaceutical Standard Report Q2/2018
VIETNAM PHARMACEUTICAL INDUSTRY
Products of the Vietnam Pharmaceutical Corporation are mostly focused on simple dosage forms, Generic form, low values, overlapping and lack of therapeutic, complex dosage drugs. The rate of new drug research investments of domestic companies accounted for only about 5% of revenue while foreign companies were 15%.
The total value of the pharmaceutical industry in 2018 was estimated at $ 5.9 million, of which a significant contribution from this growth was from imported pharmaceuticals. Although drug expenditure per capita increased sharply to 61.8 USD/person/year.
In the first 3 months of 2019, Vietnam's pharmaceutical import turnover increased by 16.2% compared to the same period in 2018. Pharmaceutical exports rose by 2% compared to the same period in 2018, in which, TTR was the main payment form, accounting for 93%. CIF delivery conditions accounted for about 70%, FOB made up 8.6% of total export orders.
According to the information about drug prices declared on the website of the Drug Administration - Ministry of Health, from the beginning of the year to April 19, 2019: Regarding imported drugs, there were 551 drug items whose prices were declared , 68 drug items whose prices were re-declared; About domestic drugs, there were 1,284 drug items of price declaration, 173 drug items whose prices were re-declared.
Pharmaceutical products are essential needs, so the economic growth has almost no effect on the industry's growth rate, the driving force is protected from state policies. The M&A trend between domestic and foreign enterprises is strong for both manufacturing and distribution groups. The Vietnam Pharmaceutical industry is forecast to continue to grow in double digits.
Products of the Vietnam Pharmaceutical Corporation are mostly focused on simple dosage forms, Generic form, low values, overlapping and lack of therapeutic, complex dosage drugs. The rate of new drug research investments of domestic companies accounted for only about 5% of revenue while foreign companies were 15%.
The total value of the pharmaceutical industry in 2018 was estimated at $ 5.9 million, of which a significant contribution from this growth was from imported pharmaceuticals. Although drug expenditure per capita increased sharply to 61.8 USD/person/year.
In the first 3 months of 2019, Vietnam's pharmaceutical import turnover increased by 16.2% compared to the same period in 2018. Pharmaceutical exports rose by 2% compared to the same period in 2018, in which, TTR was the main payment form, accounting for 93%. CIF delivery conditions accounted for about 70%, FOB made up 8.6% of total export orders.
According to the information about drug prices declared on the website of the Drug Administration - Ministry of Health, from the beginning of the year to April 19, 2019: Regarding imported drugs, there were 551 drug items whose prices were declared , 68 drug items whose prices were re-declared; About domestic drugs, there were 1,284 drug items of price declaration, 173 drug items whose prices were re-declared.
Pharmaceutical products are essential needs, so the economic growth has almost no effect on the industry's growth rate, the driving force is protected from state policies. The M&A trend between domestic and foreign enterprises is strong for both manufacturing and distribution groups. The Vietnam Pharmaceutical industry is forecast to continue to grow in double digits.
ABBREVIATIONS
Report summary
1. BUSINESS ENVIRONMENT
1.1. Macroeconomic situation
1.2. Legal framework
2. PHARMACEUTICAL INDUSTRY OVERVIEW
2.1. Global Pharmaceutical Industry
2.1.1. Production - Consumption
2.2. Vietnam Pharmaceutical Industry Overview
2.2.1. History of Vietnam Pharmaceutical Industry
2.2.2. Industry Position
2.2.3. Industry Scale and Feature
2.2.4. Value Chain of Vietnam Pharmaceutical Industry
2.2.5. Production
2.2.6. Consumption
2.2.7. Export - Import
2.2.8. Price movements
2.3. Industry planning
2.4. Driving forces and forecast
3. ENTERPRISE ANALYSIS
3.1. Profitability Ratios
3.2. Cost structure
3.3. Asset Management Ratios
3.4. Capital Structure
3.5. Solvency
3.6. Return on Investment
Report summary
1. BUSINESS ENVIRONMENT
1.1. Macroeconomic situation
1.2. Legal framework
2. PHARMACEUTICAL INDUSTRY OVERVIEW
2.1. Global Pharmaceutical Industry
2.1.1. Production - Consumption
2.2. Vietnam Pharmaceutical Industry Overview
2.2.1. History of Vietnam Pharmaceutical Industry
2.2.2. Industry Position
2.2.3. Industry Scale and Feature
2.2.4. Value Chain of Vietnam Pharmaceutical Industry
2.2.5. Production
2.2.6. Consumption
2.2.7. Export - Import
2.2.8. Price movements
2.3. Industry planning
2.4. Driving forces and forecast
3. ENTERPRISE ANALYSIS
3.1. Profitability Ratios
3.2. Cost structure
3.3. Asset Management Ratios
3.4. Capital Structure
3.5. Solvency
3.6. Return on Investment
LIST OF TABLES
Table 1: Statistics of drug production by category, 2013 –2018e
Table 2: Vietnam’s top import partners, 2018
Table 3: Top exporting enterprises, 2018
Table 4: Price movements of some major drugs in the market, 12/2017 – 12/2018
Table 5: The difference in the price of some drugs at some drug stores, 2017
Table 6: The number of medical facilities, 2010 - 2016
Table 7: 10 typical pharmaceutical enterprises in 2017
Table 1: Statistics of drug production by category, 2013 –2018e
Table 2: Vietnam’s top import partners, 2018
Table 3: Top exporting enterprises, 2018
Table 4: Price movements of some major drugs in the market, 12/2017 – 12/2018
Table 5: The difference in the price of some drugs at some drug stores, 2017
Table 6: The number of medical facilities, 2010 - 2016
Table 7: 10 typical pharmaceutical enterprises in 2017
LIST OF FIGURES
Figure 1: GDP growth rate by quarter (%), 2016 - 2019
Figure 2: Consumer drug and medical service price index, 2012 - Q1/2019
Figure 3: VND/USD exchange rate, 1/2013 - 3/2019
Figure 4: VND/CNY exchange rate, 1/2016 – 3/2019
Figure 5: Population structure, 1999 - 2018
Figure 6: Population and population growth, 2006 -2018
Figure 7: The number of new drugs authorized by the FDA, 2010 - 2018
Figure 8: Investment in R&D in the world, 2010 - 2024f
Figure 9: Top 10 enterprises with the largest R & D costs, 2017
Figure 10: Top 10 enterprises with the largest R & D costs, 2024
Figure 11: Revenue of the global pharmaceutical industry, 2010 - 2017e
Figure 12: Worldwide prescription drug sales, 2010 - 2017
Figure 13: Worldwide Drug Sales by Technology, 2010 - 2017
Figure 14: Drug consumption by types, 2011 - 2017
Figure 15: Drug consumption by group, 2017
Figure 16: Top 10 therapeutic classes by estimated global pharmaceutical sales*, 2017
Figure 17: Average capital, fixed assets and long-term average investment of enterprises, 2010 - 2017
Figure 18: Number of enterprises and workers in medicine, chemical and pharmaceutical manufacturing sectors, 2010 - 2017
Figure 19: Revenue and profit before tax, 2010 - 2017
Figure 20: Domestic pharmaceutical production value, 2010 - 2018e
Figure 21: Market value of pharmaceutical industry, 2010 - 2018e
Figure 22: Value ratio of domestically produced medicines in Vietnam, 2010 – 2018e
Figure 23: Domestically produced medicine consumption, 2010 – 3/2019e
Figure 24: Spending on medicines in Vietnam, 2009 – 2017e
Figure 25: Spending on medicines per capita in some countries, 2017e
Figure 26: Medicines consumption structure by channel, 2011- 2018e
Figure 27: Current status of Patented and Generic drugs, 2011 - 2018e
Figure 28: Market value of prescription drugs (ETC), 2011 – 2017e
Figure 29: Market value of non-prescription drugs (OTC), 2010 – 2017e
Figure 30: OTC revenue structure by selling channel, 2018
Figure 31: Patened drugs (Patent), 2010 – 2018e
Figure 32: Generic drug market, 2010 – 2018e
Figure 33: Import of pharmaceuticals, 2012 - Q1/2019e
Figure 34: Pharmaceutical imports, 2017 – Q1/2019e
Figure 35: Pharmaceuticals imports from India, 2013 – Q1/2019
Figure 36: Top importing enterprises *, Q1/2019
Figure 37: Pharmaceutical export, 2012 - Q1/2019
Figure 38: Export structure by country, Q1/2019
Figure 39: Rate of drug re-price (increase), 2013 - 2018
Figure 40: Total healthcare expenses, 2010 – 2017f
Figure 41: Population tower, 2018
Figure 42: Over-60 population growth in the world, 1950 – 2050
Figure 43: DHG’s Shareholder structure, 2018
Figure 44: TRA ‘s Shareholder structure, 2018
Figure 45: DMC ‘s Shareholder structure, 2018
Figure 46: Imexpharm ‘s Shareholder structure, 2018
Figure 47: OPC ‘s Shareholder structure, 2018
Figure 48: SPM ‘s Shareholder structure, 2018
Figure 49: Vimedimex ‘s Shareholder structure, 2018
Figure 50: DHT ‘s Shareholder structure, 2018
Figure 51: DBT ‘s Shareholder structure, 2018
Figure 52: LDP ‘s Shareholder structure, 2018
Figure 53: Gross profit margin, 2017 - 2018
Figure 54: Selling expenses, 2017 - 2018
Figure 55: Enterprise management costs, 2017 - 2018
Figure 56: Inventory days, 2018
Figure 57: Average collection period, 2018
Figure 58: Asset rotation, 2018
Figure 59: Self-financing ratio, 2017 - 2018
Figure 60: Solvency, 2017 - 2018
Figure 61: Profit ratio, 2017 - 2018
Figure 1: GDP growth rate by quarter (%), 2016 - 2019
Figure 2: Consumer drug and medical service price index, 2012 - Q1/2019
Figure 3: VND/USD exchange rate, 1/2013 - 3/2019
Figure 4: VND/CNY exchange rate, 1/2016 – 3/2019
Figure 5: Population structure, 1999 - 2018
Figure 6: Population and population growth, 2006 -2018
Figure 7: The number of new drugs authorized by the FDA, 2010 - 2018
Figure 8: Investment in R&D in the world, 2010 - 2024f
Figure 9: Top 10 enterprises with the largest R & D costs, 2017
Figure 10: Top 10 enterprises with the largest R & D costs, 2024
Figure 11: Revenue of the global pharmaceutical industry, 2010 - 2017e
Figure 12: Worldwide prescription drug sales, 2010 - 2017
Figure 13: Worldwide Drug Sales by Technology, 2010 - 2017
Figure 14: Drug consumption by types, 2011 - 2017
Figure 15: Drug consumption by group, 2017
Figure 16: Top 10 therapeutic classes by estimated global pharmaceutical sales*, 2017
Figure 17: Average capital, fixed assets and long-term average investment of enterprises, 2010 - 2017
Figure 18: Number of enterprises and workers in medicine, chemical and pharmaceutical manufacturing sectors, 2010 - 2017
Figure 19: Revenue and profit before tax, 2010 - 2017
Figure 20: Domestic pharmaceutical production value, 2010 - 2018e
Figure 21: Market value of pharmaceutical industry, 2010 - 2018e
Figure 22: Value ratio of domestically produced medicines in Vietnam, 2010 – 2018e
Figure 23: Domestically produced medicine consumption, 2010 – 3/2019e
Figure 24: Spending on medicines in Vietnam, 2009 – 2017e
Figure 25: Spending on medicines per capita in some countries, 2017e
Figure 26: Medicines consumption structure by channel, 2011- 2018e
Figure 27: Current status of Patented and Generic drugs, 2011 - 2018e
Figure 28: Market value of prescription drugs (ETC), 2011 – 2017e
Figure 29: Market value of non-prescription drugs (OTC), 2010 – 2017e
Figure 30: OTC revenue structure by selling channel, 2018
Figure 31: Patened drugs (Patent), 2010 – 2018e
Figure 32: Generic drug market, 2010 – 2018e
Figure 33: Import of pharmaceuticals, 2012 - Q1/2019e
Figure 34: Pharmaceutical imports, 2017 – Q1/2019e
Figure 35: Pharmaceuticals imports from India, 2013 – Q1/2019
Figure 36: Top importing enterprises *, Q1/2019
Figure 37: Pharmaceutical export, 2012 - Q1/2019
Figure 38: Export structure by country, Q1/2019
Figure 39: Rate of drug re-price (increase), 2013 - 2018
Figure 40: Total healthcare expenses, 2010 – 2017f
Figure 41: Population tower, 2018
Figure 42: Over-60 population growth in the world, 1950 – 2050
Figure 43: DHG’s Shareholder structure, 2018
Figure 44: TRA ‘s Shareholder structure, 2018
Figure 45: DMC ‘s Shareholder structure, 2018
Figure 46: Imexpharm ‘s Shareholder structure, 2018
Figure 47: OPC ‘s Shareholder structure, 2018
Figure 48: SPM ‘s Shareholder structure, 2018
Figure 49: Vimedimex ‘s Shareholder structure, 2018
Figure 50: DHT ‘s Shareholder structure, 2018
Figure 51: DBT ‘s Shareholder structure, 2018
Figure 52: LDP ‘s Shareholder structure, 2018
Figure 53: Gross profit margin, 2017 - 2018
Figure 54: Selling expenses, 2017 - 2018
Figure 55: Enterprise management costs, 2017 - 2018
Figure 56: Inventory days, 2018
Figure 57: Average collection period, 2018
Figure 58: Asset rotation, 2018
Figure 59: Self-financing ratio, 2017 - 2018
Figure 60: Solvency, 2017 - 2018
Figure 61: Profit ratio, 2017 - 2018
